

(n=6) *IL28B* genotypes on days 1, 3, 7 and 14 (-1.2 vs -1.3, -1.4 vs -1.4, -1.8 vs -1.7, and -2.3 vs -1.9 log copies/ml) (figure 4A). Moreover, we prepared two additional serum samples from the other HCV-1b patients (serum B and C)²¹ to confirm the influence of *IL28B* genotype in early viral kinetics during IFN treatment. After establishing persistent infection with new HCV-1b strains in all chimeric mice, they were also administered four times injections of the bolus dose of peg-IFN- α 2a for 2 weeks (figure 4B,C). In a similar fashion, no significant difference in HCV-RNA reduction in chimeric mice sera was observed between favourable and unfavourable *IL28B* genotypes.


Expression levels of ISG in chimeric mice livers

Because chimeric mice have the characteristic of severe combined immunodeficiency, the viral kinetics in chimeric mice

sera during IFN treatment could be contributed by the innate immune response of HCV-infected human hepatocytes. Therefore, ISG expression levels in mice livers transplanted with human hepatocytes were compared between favourable and unfavourable *IL28B* genotypes (figure 5).

As shown in figure 5A, ISG expression levels in mice livers were measured at 8 h and 24 h after IFN treatment. The levels of representative antiviral ISG (eg, myxovirus resistance protein A, oligoadenylate synthetase 1, RNA-dependent protein kinase) and other ISG for promoting antiviral signalling (eg, Toll-like receptor 3, retinoic acid-inducible gene 1) were significantly induced at least 8 h after treatment, and prolonged at 24 h. No significant difference in ISG expression levels in HCV-infected livers was observed between favourable and unfavourable *IL28B* genotypes. The other inoculum for persistent infection of HCV-1b also demonstrated no significant difference in ISG

Figure 5 Intrahepatic interferon (IFN)-stimulated gene (ISG) expression levels in the pegylated interferon α (peg-IFN- α)-treated chimeric mice having human hepatocytes containing homozygous favourable allele (rs8099917 TT; MA) and heterozygous unfavourable allele (rs8099917 TG; HE) were measured and expressed relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger RNA. Data are represented as mean+SD. (A) Time kinetics of ISG after administration of the peg-IFN- α in serum A-infected chimeric mice (n=3, each genotype). Comparison of ISG expression levels at (B) 8 h in serum B-infected mice and (C) 24 h in serum C-infected mice after administering peg-IFN- α (n=3, each genotype). Predesigned real-time PCR assay of *IL28B* transcript purchased from Applied Biosystems can be cross-reactive to *IL28A* transcript. * $p < 0.05$. MxA, myxovirus resistance protein A; OAS1, oligoadenylate synthetase 1; PKR, RNA-dependent protein kinase; RIG-1, retinoic acid-inducible gene 1; TLR3, Toll-like receptor 3.



Viral hepatitis

expression levels between favourable and unfavourable *IL28B* genotypes (figure 5B,C). Interestingly, IFN- λ expression levels by treatment of peg-IFN- α were significantly induced in HCV-infected human hepatocytes harbouring the favourable *IL28B* genotype (figure 5 A–C).

DISCUSSION

Several recent studies have demonstrated a marked association between the chronic hepatitis C treatment response^{6–9} and SNP (rs8099917, rs8103142 and rs12979860) near or within the region of the *IL28B* gene, which affected the viral dynamics during peg-IFN- α plus ribavirin therapy in Caucasian, African American and Hispanic individuals.¹³

It has been reported that when patients with chronic hepatitis C are treated by IFN- α or peg-IFN- α plus ribavirin, HCV-RNA generally declines after a 7–10 h delay.²⁵ The typical decline is biphasic and consists of a rapid first phase lasting for approximately 1–2 days during which HCV-RNA may fall 1–2 logs in patients infected with genotype 1, and subsequently a slower second phase of HCV-RNA decline.²⁶ The viral kinetics had a predictive value in evaluating antiviral efficacy.¹⁴ In this study, biphasic decline of the HCV-RNA level during peg-IFN- α treatment was observed in both patients and chimeric mice infected with HCV genotype 1; however, in the first and second phases of viral kinetics, a difference between *IL28B* genotypes was observed only in HCV-infected patients; a more rapid decline in serum HCV-RNA levels after administering peg-IFN- α plus ribavirin was confirmed in patients with the TT genotype of rs8099917 compared to those with the TG/GG genotype.

On the other hand, in-vivo data using the chimeric mouse model showed no significant difference in the reduction of HCV-RNA titers in mouse serum among four different lots of human hepatocytes containing *IL28B* favourable (rs8099917 TT) or unfavourable (rs8099917 TG) genotypes, which was confirmed by the inoculation of two additional HCV strains. These results indicated that variants of the *IL28B* gene in donor hepatocytes had no influence on the response to peg-IFN- α under immunosuppressive conditions, suggesting that the immune response according to *IL28B* genetic variants could contribute to the first and second phases of HCV-RNA decline and might be critical for HCV clearance by peg-IFN- α -based therapy.

Two recent studies indeed revealed an association between the *IL28B* genotype and the expression level of hepatic ISG in human studies.^{27–28} Quiescent hepatic ISG before treatment among patients with the *IL28B* favourable genotype have been associated with sensitivity to exogenous IFN treatment and viral eradication; however, it is difficult to establish whether the hepatic ISG expression level contributes to viral clearance independently or appears as a direct consequence of the *IL28B* genotype. Another recent study addressed this question and the results suggested that there is no absolute correlation with the *IL28B* genotype and hepatic expression of ISG.²⁹ Our results on the hepatic ISG expression level in immunodeficient chimeric mice also suggested that no significant difference in ISG expression levels was observed between favourable and unfavourable *IL28B* genotypes. However, these results were not consistent with a previous report using chimeric mice that the favourable *IL28B* genotype was associated with an early reduction in HCV-RNA by ISG induction.³⁰ The reasons for the discrepancy might depend on the dose and type of IFN treatment, as well as the time point when ISG expression was examined in the liver. In addition, although IFN- λ transcript levels measured in peripheral blood mononuclear cells or liver revealed inconsistent

results in the context of an association with the *IL28B* genotype,^{7–8} our preliminary assay on the *IL28A*, *IL28B* and *IL29* transcripts in the liver first indicated that the induction of IFN- λ on peg-IFN- α administration could be associated with the *IL28B* genotype. Therefore, the induction of IFN- λ followed by immune response might contribute to different viral kinetics and treatment outcomes in HCV-infected patients, because no difference was found in chimeric mice without immune response.

It has also been reported that the mechanism of the association of genetic variations in the *IL28B* gene and spontaneous clearance of HCV may be related to the host innate immune response.¹¹ Interestingly, participants with seroconversion illness with jaundice were more frequently rs8099917 homozygous favourable allele (TT) than other genotypes (32% vs 5%, $p=0.047$). This suggests that a stronger immune response during the acute phase of HCV infection among patients with the *IL28B* favourable genotype would induce more frequent spontaneous clearance of HCV.

Taking into account both the above results in acute HCV infection and our results conducted on chimeric mice that have the characteristic of immunodeficiency, it is suggested that the response to peg-IFN- α associated with the variation in *IL28B* alleles in chronic hepatitis C patients would be composed of the intact immune system.

Acknowledgements The authors would like to thank Kyoko Ito of Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan for doing the quantification of gene-expression assays.

Contributors YT and MM conceived the study. TW and FS and YT conducted the study equally. TW and FS coordinated the analysis and manuscript preparation. All the authors had input into the study design, patient recruitment and management or mouse management and critical revision of the manuscript for intellectual content. TW, FS and YT contributed equally.

Funding This study was supported by a grant-in-aid from the Ministry of Health, Labour, and Welfare of Japan (H22-kannen-005) and the Ministry of Education, Culture, Sports, Science and Technology, Japan, and grant-in-aid for research in Nagoya City University.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of each ethics committee at the Nagoya City University and Nagasaki Medical Center (see supplementary information, available online only).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Ray Kim W. Global epidemiology and burden of hepatitis C. *Microbes Infect* 2002;4:1219–25.
2. Foster GR. Past, present, and future hepatitis C treatments. *Semin Liver Dis* 2004;24(Suppl. 2):97–104.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975–82.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–65.
5. Mihm U, Herrmann E, Sarrazin C, et al. Review article: predicting response in hepatitis C virus therapy. *Aliment Pharmacol Ther* 2006;23:1043–54.
6. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399–401.
7. Suppiah V, Moldovan M, Ahlenstiel G, et al. *IL28B* is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009;41:1100–4.
8. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of *IL28B* with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105–9.
9. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in *IL28B* is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010;138:1338–45.

10. **Tanaka Y**, Nishida N, Sugiyama M, *et al.* lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. *Hepatol Res* 2010;**40**:449–60.
11. **Thomas DL**, Thio CL, Martin MP, *et al.* Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009;**461**:798–801.
12. **Grebely J**, Petoumenos K, Hellard M, *et al.* Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. *Hepatology* 2010;**52**:1216–24.
13. **Thompson AJ**, Muir AJ, Sulkowski MS, *et al.* Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology* 2010;**139**:120–29.
14. **Layden-Almer JE**, Layden TJ. Viral kinetics in hepatitis C virus: special patient populations. *Semin Liver Dis* 2003;**23**(Suppl. 1):29–33.
15. **Heckel JL**, Sandgren EP, Degen JL, *et al.* Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. *Cell* 1990;**62**:447–56.
16. **Rhim JA**, Sandgren EP, Degen JL, *et al.* Replacement of diseased mouse liver by hepatic cell transplantation. *Science* 1994;**263**:1149–52.
17. **Tateno C**, Yoshizane Y, Saito N, *et al.* Near completely humanized liver in mice shows human-type metabolic responses to drugs. *Am J Pathol* 2004;**165**:901–12.
18. **Mercer DF**, Schiller DE, Elliott JF, *et al.* Hepatitis C virus replication in mice with chimeric human livers. *Nat Med* 2001;**7**:927–33.
19. **Tsuge M**, Hiraga N, Takaishi H, *et al.* Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. *Hepatology* 2005;**42**:1046–54.
20. **Kurbanov F**, Tanaka Y, Chub E, *et al.* Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. *J Infect Dis* 2008;**198**:1448–56.
21. **Kurbanov F**, Tanaka Y, Matsuura K, *et al.* Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. *J Infect Dis* 2010;**201**:1663–71.
22. **Inoue K**, Umehara T, Ruegg UT, *et al.* Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. *Hepatology* 2007;**45**:921–8.
23. **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 2001;**25**:402–8.
24. **Silver N**, Best S, Jiang J, *et al.* Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. *BMC Mol Biol* 2006;**7**:33.
25. **Dahari H**, Layden-Almer JE, Perelson AS, *et al.* Hepatitis C viral kinetics in special populations. *Curr Hepat Rep* 2008;**7**:97–105.
26. **Neumann AU**, Lam NP, Dahari H, *et al.* Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 1998;**282**:103–7.
27. **Honda M**, Sakai A, Yamashita T, *et al.* Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. *Gastroenterology* 2010;**139**:499–509.
28. **Urban TJ**, Thompson AJ, Bradrick SS, *et al.* IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. *Hepatology* 2010;**52**:1888–96.
29. **Dill MT**, Duong FH, Vogt JE, *et al.* Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. *Gastroenterology* 2011;**140**:1021–31.
30. **Hiraga N**, Abe H, Imamura M, *et al.* Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. *Hepatology* 2011;**54**:764–71.



Short communication

Translocation of outer mitochondrial membrane Tom70 induces interferon response and is impaired by hepatitis C virus NS3

Yuri Kasama^a, Makoto Saito^a, Takashi Takano^b, Tomohiro Nishimura^c, Masaaki Satoh^{a,d}, Zhongzhi Wang^a, Salem Nagla Elwy Salem Ali^{a,e}, Shinji Harada^e, Michinori Kohara^f, Kyoko Tsukiyama-Kohara^{a,*}

^a Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo Kumamoto City, Kumamoto 860-8556, Japan

^b Division of Veterinary Public Health, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-8602, Japan

^c KAKETSUKEN, Kyokushi, Kikuchi, Kumamoto 869-1298, Japan

^d Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

^e Department of Medical Virology, Faculty of Life Sciences, Kumamoto University, Japan

^f Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan

ARTICLE INFO

Article history:

Received 5 September 2011

Received in revised form 13 October 2011

Accepted 13 October 2011

Available online 20 October 2011

Keywords:

HCV

Tom70

MAVS

IFN

IRF-3

NS3

ABSTRACT

Hepatitis C virus (HCV) elevated expression of the translocation of outer mitochondrial membrane Tom70. Interestingly, overexpression of Tom70 induces interferon (IFN) synthesis in hepatocytes, and it was impaired by HCV. Here, we addressed the mechanism of this impairment. The HCV NS3/4A protein induced Tom70 expression. The HCV NS3 protein interacted in cells, and cleaved the adapter protein mitochondrial anti-viral signaling (MAVS). Ectopic overexpression of Tom70 could not inhibit this cleavage. As a result, IRF-3 phosphorylation was impaired and IFN- β induction was suppressed. These results indicate that MAVS works upstream of Tom70 and the cleavage of MAVS by HCV NS3 protease suppresses signaling of IFN induction.

© 2011 Elsevier B.V. All rights reserved.

Type I interferon (IFN) induction is the front line of host defense against viral infection. Intracellular double-stranded RNA is a viral replication intermediate and contains pathogen-associated molecular patterns (PAMPs) (Saito et al., 2008) that are recognized by pathogen-recognition receptors (PRRs) to induce IFN. One PRR family includes the Toll-like receptors (TLRs), which are predominantly expressed in the endosome (Heil et al., 2004). Another route of IFN induction takes place in the cytosol through activation of specific RNA helicases, such as retinoic acid-inducible (RIG)-I and melanoma differentiation associated gene 5 (MDA5). The ligand for RIG-I is an uncapped 5' triphosphate RNA, which is found in viral RNAs of the *Flaviviridae* family, including hepatitis C virus (HCV), paramyxovirus, and rhabdoviruses (Kato et al., 2006). MDA5 recognizes viruses with protected 5' RNA ends, for example,

picornaviruses (Hornung et al., 2006). The adapter protein that links the RNA helicase to the downstream MAPK, NF- κ B, and IRF-3 signaling pathways is referred to as the mitochondrial anti-viral signaling (MAVS) protein (Seth et al., 2005); alternative names include IPS-1, interferon-promoter stimulator 1; VISA, virus-induced signaling adaptor; and CARDIF, CARD adapter inducing IFN. HCV nonstructural protein 3 (NS3) possesses a serine protease domain at the N terminus (amino acids (aa) 1–180) and has been found to cleave adaptor proteins, MAVS at aa 508 (Meylan et al., 2005) and Toll/IL-1R domain-containing adapter inducing IFN- β -deficient (TRIF at aa 372; Ferreon et al., 2005). These cleavages provoke abrogation of the induction of the IFN pathway.

The translocation of the outer membrane (TOM) is responsible for initial recognition of mitochondrial preproteins in the cytosol (Baker et al., 2007; Neupert and Herrmann, 2007). The TOM machinery consists of 2 import receptors, Tom20 and Tom70, and, along with several other subunits, comprises the general import pore (Abe et al., 2000). Recently, Tom70 was found to interact with MAVS (Liu et al., 2010). Ectopic expression or silencing of Tom70, respectively, enhanced or impaired IRF3-mediated gene expression and IFN- β production. Sendai virus infection accelerated the

* Corresponding author. Present address: Transboundary Animal Diseases Center, Faculty of Agriculture, Kagoshima University, 1-21-24 Korimoto Kagoshima-shi, Kagoshima 890-0065, Japan. Tel.: +81 99 285 3589/96 373 5560; fax: +81 99 285 3589/96 373 5562.

E-mail address: kkohara@kumamoto-u.ac.jp (K. Tsukiyama-Kohara).




Fig. 1. HCV induces overexpression of Tom70 but impairs Tom70-induced IFN synthesis. (A) RzM6 cells (HCV-) and RzM6-LC cells (HCV+) were transfected with siRNAs of control (non-target siRNA#3: Thermo Fisher Scientific), HCV (R5: 5'-GUCUCGUAGACCGUGCAUu-3'), DHCR24 (Nishimura et al., 2009), and Tom70 (Takano et al., 2011a). Control cells were mock-transfected. Tom70 protein was detected with MAb2-243a (Takano et al., 2011a) and actin protein was detected as an internal control (lower column). (B) HuH-7 cells were infected with HCV JFH1 strain; Tom70 protein and actin protein were detected. (C) The HCV replicon cells (FLR3-1; Takano et al., 2011b) were transfected with siRNAs (control, HCV (R7: 5'-GUCUCGUAGACCGUGCACCAu-3'), Tom70; 0.1, 0.3, 1, 3 nM) and HCV replication activity was measured with luciferase activity using the Bright-Glo luciferase assay kit (Promega). Cell viability was measured using WST-8 (Dojindo) reagent. Ratio with those of control siRNA treatment was calculated. Vertical bars were S.D. (D) HCV replicon cells (FLR3-1) were transfected with control, HCV (R7) and Tom70 siRNAs (0.1, 0.3 nM) and Tom70, NS5A and actin proteins were detected.

Tom70-mediated IFN induction and the interaction of Tom70 with MAVS. These recent findings indicated that Tom70 might be a critical mediator during IFN induction (Liu et al., 2010).

We previously observed that HCV induces Tom70 and is related to the apoptotic response (Takano et al., 2011a). However, no synergistic effect was observed for IFN induction by Tom70 and HCV. Therefore, in the present study, we have investigated the mechanism of modification of the Tom70-induced IFN synthesis pathway by HCV and clarified a finely balanced system regulated by viral protein.

The expression of Tom70 protein was examined using western blotting and modification by HCV was characterized (Fig. 1A).

The level of Tom70 protein was increased in RzM6-LC cells compared with that in RzM6-0d cells (Tsukiyama-Kohara et al., 2004). The full-length HCV-RNA expression was induced by 4-hydroxy-tamoxifen (100nM) and passaged for more than 44 days in RzM6-LC cells, and HCV expression was not induced in RzM6-0d cells. Silencing of HCV expression by siRNA (R5; Thermo Scientific) abolished core protein expression, and decreased the level of Tom70 protein expression in RzM6-LC cells (Fig. 1A). Silencing of Tom70 by siRNA significantly decreased the level of HCV core protein expression in RzM6-LC cells (Fig. 1A). The siRNA against 3-beta-hydroxysterol-delta24 reductase (DHCR24) slightly decreased the level of Tom70 protein. In contrast, the




Fig. 2. Tom70-induced IFN synthesis was impaired by HCV. (A) RzM6-0d cells and LC cells were transfected with mock-vector, control pcDNA vector (vec.), or pcDNA-Tom70 expression vector, and the amount of IFN- β mRNA was measured by RTD-PCR and normalized to the amount of GAPDH mRNA using Gene expression assay kit (GE-Healthcare). Poly(I-C) (GE Healthcare) (5 μ g) was transfected with RNAi Max reagent (Invitrogen) and IFN- β mRNA was measured after 6 h of poly(I-C) treatment. Vertical bars indicate S.D. * $p < 0.05$. (B) HuH-7 cells were transfected with mock-vector, control vector, or Tom70 expression vector, and the amount of IFN- β mRNA was measured by RTD-PCR and normalized to the amount of GAPDH mRNA. Vertical bars indicate S.D. * $p < 0.05$.

control siRNA did not have a significant effect on Tom70 protein expression.

We next examined the effects of HCV JFH-1 (Wakita et al., 2005) infection on Tom70 expression (Fig. 1B). Infection with HCV significantly increased the level of Tom70 protein expression. We also examine the role of Tom70 in HCV replication (Fig. 1C and D). Silencing of Tom70 by siRNA decreased the HCV replication in a dose dependent manner.

Thus, HCV induces Tom70 expression, and Tom70 is involved in viral replication.

It was recently shown that Tom70 recruits TBK1/IRF3 to mitochondria by binding to Hsp90 and inducing IFN- β synthesis (Liu et al., 2010). Therefore, we examined the effects of Tom70 overexpression on IFN synthesis and modification by HCV (Fig. 2). Level of IFN- β mRNA synthesis was quantitated by real-time detection (RTD) PCR. Overexpression of Tom70 by transfection of pcDNA6-Tom70 (Takano et al., 2011a) induced IFN- β mRNA synthesis in the absence of HCV after poly(I-C) treatment (RzM6-0d cells). However, the Tom70-mediated induction of IFN- β mRNA transcription was impaired in the presence of HCV (RzM6-LC cells) (Fig. 2A). Overexpression of Tom70 induced IFN- β mRNA synthesis in HuH-7 cells (Fig. 2B). Induction of IFN- β mRNA was lower in HuH-7 cells than HepG2 based RzM6 cells, which might be due to the defect in IFN induction system in HuH-7 cells (Preiss et al., 2008).

We have further addressed the mechanism of impairment of IFN- β mRNA transcription by HCV.

To identify the viral protein that was responsible for the induction of Tom70, we examined the Tom70 protein expression levels in HCV core, E1, E2, NS2, NS3/4A, NS4B, NS5A, and NS5B protein-expressing cells (data not shown), and Tom70 protein expression level was highest in the NS3/4A-expressing cells than was observed in cells expressing other proteins (Fig. 3A, data not shown), indicating an effect of HCV NS3/4A protein on Tom70 expression.

The expression vector of Myc- and His-tagged Tom70 was transfected into the empty control or NS3/4A-expressing cells and immunoprecipitated with anti-Myc antibody (Suppl. Fig. 1A). Results showed that Myc-Tom70 was precipitated in both cells (right panel) and NS3 protein was specifically precipitated by

anti-Myc antibody in the NS3/4A-expressing cells (left panel). NS4A protein could not be detected (data not shown).

We next stained the NS3/4A-expressing cells with anti-NS3 and -Tom70 antibodies, and observed with confocal microscopy (Suppl. Fig. 1B). The signal of NS3 protein was clearly merged with that of Tom70, strongly supporting the possibility that the NS3 protein co-localizes with the Tom70 protein.

To clarify the effect of Tom70 on NS3, we transfected NS3/4A-expressing cells with the siRNA of Tom70 (Fig. 3A). Silencing of Tom70 decreased the level of NS3 protein in cells, but did not influence the levels of the MAVS and NF- κ B proteins. These results suggest the possibility that Tom70 may increase the stability of NS3 protein in cells.

Tom70 reportedly interacts with MAVS during viral infection (Liu et al., 2010). Therefore, we examined the MAVS protein in cells expressing either the control empty or NS3/4A lenti-virus vector (Fig. 3B). Cleavage of MAVS (indicated as Δ MAVS) was observed in NS3/4A protein-expressing cells, as was reported previously (Meylan et al., 2005). Overexpression of Tom70 did not have a significant effect on the MAVS expression level and did not prevent MAVS cleavage by NS3. IRF-3 phosphorylation was suppressed in NS3/4A-expressing cells and was not influenced by Tom70 overexpression. The induction of IFN- β was impaired in NS3/4A-expressing cells, even in the presence of Tom70 overexpression (Fig. 3C). These data may indicate that MAVS exists upstream of Tom70 and that cleavage of MAVS by NS3/4A impaired the downstream signaling activation of IRF-3 phosphorylation (Suppl. Fig. 2).

Mitochondria provide a substantial platform for the regulation of IFN signaling. The MAVS adapter protein is a member of the family of RIG-I like receptors (RLRs), which links the mitochondria to the mammalian antiviral defense system (Seth et al., 2005). Proteomic studies have demonstrated that MAVS interacts with Tom70 (Liu et al., 2010). This interaction was accelerated by Sendai virus infection and synergized with ectopic expression of Tom70 to significantly increase the production of IFN- β (Liu et al., 2010). The results of the present study revealed that infection with HCV induced Tom70 expression, but the presence of HCV impaired IFN




Fig. 3. Silencing of Tom70 decreased the level of NS3 and cleavage of MAVS by NS3/4A impaired IRF-3 phosphorylation even in the presence of Tom70. (A) Empty or NS3/4A-lenti virus vector expressing HepG2 cells were transfected with control siRNA and Tom70 siRNA or mock-transfected (non) as a control. MAVS, NS3, Tom70, and actin proteins were detected by western blot. (B) Empty or NS3/4A-expressing HepG2 cells were transfected with control pcDNA vector (vec.) and pcDNA6 (Invitrogen)-Tom70 or mock-transfected (non) as a control. NS3, Tom70, phosphorylated IRF-3, MAVS, and actin proteins were examined by western blot. (C) IFN-β mRNA was measured by RTD-PCR and normalized with GAPDH mRNA amount in empty or NS3/4A expressing cells with transfection of mock (non), pcDNA-vector (vec.) or pcDNA-Tom70 (Tom70). Poly(I-C) was treated, as described in the legend of Fig. 2.

induction. It has been reported that the C-terminal transmembrane domain (TM) of MAVS interacts with the N-terminal transmembrane domain of Tom70 (Liu et al., 2010). The HCV NS3 protein cleaves MAVS at residue 508 (Meylan et al., 2005), which should impair the interaction of MAVS and Tom70. This may attenuate the downstream signaling pathway (TBK-IRF3) and the induction of IFN synthesis (Suppl. Fig. 2). In our study, the level of NF-κB protein was not significantly influenced by Tom70 in the presence or absence of NS3. This may indicate that other pathways, such as TLR3 and downstream pathways, might compensate to maintain the NF-κB protein expression level in the absence of the MAVS-Tom70 signaling pathway.

Infection with HCV induced expression of Tom70, but the activation of the IFN signaling pathway was abrogated by the HCV NS3 protease. These findings indicate that recovery of the MAVS-Tom70 pathway may be a means to increase the efficacy of IFN therapy against HCV infection.

Recently, we observed that overexpression of Tom70 increased the resistance to the TNFα-induced apoptotic response (Takano

et al., 2011a), indicating that Tom70 overexpression might contribute to the apoptotic resistance of HCV-infected cells and the establishment of persistent HCV infection. Thus, Tom70 might be a novel target for the regulation of HCV infection.

Acknowledgements

Authors thank Professor Yoshiharu Matsuura for providing the rabbit polyclonal NSSA antibody. This work was supported by grants from the Ministry of Health, Labor, and Welfare of Japan and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.virusres.2011.10.009.

References

- Abe, Y., Shodai, T., Muto, T., Mihara, K., Torii, H., Nishikawa, S., Endo, T., Kohda, D., 2000. Structural basis of presequence recognition by the mitochondrial protein import receptor Tom20. *Cell* 100 (5), 551–560.
- Baker, M.J., Frazier, A.E., Gulbis, J.M., Ryan, M.T., 2007. Mitochondrial protein-import machinery: correlating structure with function. *Trends Cell Biol.* 17 (9), 456–464.
- Ferreon, J.C., Ferreon, A.C., Li, K., Lemon, S.M., 2005. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. *J. Biol. Chem.* 280 (21), 20483–20492.
- Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., Bauer, S., 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science* 303 (5663), 1526–1529.
- Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.K., Schlee, M., Endres, S., Hartmann, G., 2006. 5'-Triphosphate RNA is the ligand for RIG-I. *Science* 314 (5801), 994–997.
- Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis e Sousa, C., Matsuura, Y., Fujita, T., Akira, S., 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441 (7089), 101–105.
- Liu, X.Y., Wei, B., Shi, H.X., Shan, Y.F., Wang, C., 2010. Tom70 mediates activation of interferon regulatory factor 3 on mitochondria. *Cell Res.* 20 (9), 994–1011.
- Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., Tschopp, J., 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. *Nature* 437 (7062), 1167–1172.
- Neupert, W., Herrmann, J.M., 2007. Translocation of proteins into mitochondria. *Annu. Rev. Biochem.* 76, 723–749.
- Nishimura, T., Kohara, M., Izumi, K., Kasama, Y., Hirata, Y., Huang, Y., Shuda, M., Mukaidani, C., Takano, T., Tokunaga, Y., Nuriya, H., Satoh, M., Saito, M., Kai, C., Tsukiyama-Kohara, K., 2009. Hepatitis C virus impairs p53 via persistent over-expression of 3beta-hydroxysterol Delta24-reductase. *J. Biol. Chem.* 284 (52), 36442–36452.
- Preiss, S., Thompson, A., Chen, X., Rodgers, S., Markovska, V., Desmond, P., Visvanathan, K., Li, K., Locarnini, S., Revill, P., 2008. Characterization of the innate immune signalling pathways in hepatocyte cell lines. *J. Viral Hepat.* 15 (12), 888–900.
- Saito, T., Owen, D.M., Jiang, F., Marcotrigiano, J., Gale Jr., M., 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. *Nature* 454 (7203), 523–527.
- Seth, R.B., Sun, L., Ea, C.K., Chen, Z.J., 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. *Cell* 122 (5), 669–682.
- Takano, T., Kohara, M., Kasama, Y., Nishimura, T., Saito, M., Kai, C., Tsukiyama-Kohara, K., 2011a. Translocase of outer mitochondrial membrane 70 expression is induced by hepatitis C virus and is related to the apoptotic response. *J. Med. Virol.* 83 (5), 801–809.
- Takano, T., Tsukiyama-Kohara, K., Hayashi, M., Hirata, Y., Satoh, M., Tokunaga, Y., Tateno, C., Hayashi, Y., Hishima, T., Funata, N., Sudo, M., Kohara, M., 2011b. Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes. *J. Hepatol.* 55 (3), 512–521.
- Tsukiyama-Kohara, K., Tone, S., Maruyama, I., Inoue, K., Katsume, A., Nuriya, H., Ohmori, H., Ohkawa, J., Taira, K., Hoshikawa, Y., Shibasaki, F., Reth, M., Minatogawa, Y., Kohara, M., 2004. Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. *J. Biol. Chem.* 279 (15), 14531–14541.
- Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H.G., Mizokami, M., Bartenschlager, R., Liang, T.J., 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11 (7), 791–796.

Hepatitis C Virus Promotes Expression of the 3β -Hydroxysterol Δ 24-Reductase Through Sp1

Makoto Saito,¹ Michinori Kohara,² and Kyoko Tsukiyama-Kohara^{1*}

¹Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

²Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

Hepatitis C virus (HCV) establishes chronic infection, which often causes hepatocellular carcinoma. Overexpression of 3β -hydroxysterol Δ 24-reductase (DHCR24) by HCV has been shown to impair the p53-mediated cellular response, resulting in tumorigenesis. In the present study, the molecular mechanism by which HCV promotes the expression of DHCR24 was investigated. A significant increase in DHCR24 mRNA transcription was observed in a cell line expressing complete HCV genome, whereas no significant difference in the expression of DHCR24 was seen in cell lines expressing individual viral proteins. The 5'-flanking genomic region of DHCR24 was characterized to explore the genomic region and host factor(s) involved in the transcriptional regulation of DHCR24. As a result, the HCV response element (–167/–140) was identified, which contains AP-2 α , MZF-1, and Sp1 binding motifs. The binding affinity of the host factor to this response element was increased in nuclear extracts from cells infected with HCV and corresponded with augmented affinity of Sp1. Both mithramycin A (Sp1 inhibitor) and small interfering RNA targeting Sp1 prevented the binding of host factors to the response element. Silencing of Sp1 also downregulated the increased expression of DHCR24. The binding affinity of Sp1 to the response element was augmented by oxidative stress, whereas upregulation of DHCR24 in cells expressing HCV was blocked significantly by a reactive oxygen species scavenger. Elevated phosphorylation of Sp1 in response to oxidative stress was mediated by the ATM kinase. Thus, activation of Sp1 by oxidative stress is involved in the promotion of expression of DHCR24 by HCV. *J. Med. Virol.* 84:733–746, 2012. © 2012 Wiley Periodicals, Inc.

KEY WORDS: HCV; DHCR24; Sp1; oxidative stress

INTRODUCTION

Hepatitis C virus (HCV) causes chronic hepatitis and hepatocellular carcinoma [Koike, 2007]. The estimated worldwide prevalence of HCV infection is 2.2–3.0% (130–170 million people) [Lavanchy, 2009], and chronic HCV infection is a major global public health concern. The most effective current treatment for HCV infection comprises combination therapy with PEGylated interferon- α and ribavirin [Bruchfeld et al., 2001; Lu et al., 2008]. However, this therapy has limited clinical efficacy, as sustained virological responses develop in only about half of patients infected with HCV genotype 1 [Kohara et al., 1995; Nakamura et al., 2002]. Efforts to develop therapies to treat HCV are also hindered by the high level of viral variation and the capacity of HCV to cause chronic infection. Therefore, there is an urgent need to develop effective treatments against chronic HCV infection.

Additional supporting information may be found in the online version of this article.

Grant sponsor: Ministry of Health and Welfare of Japan; Grant sponsor: Ministry of Education, Culture, Sports, Science and Technology of Japan; Grant sponsor: Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation; Grant sponsor: Cooperative Research Project on Clinical and Epidemiological Studies of Emerging and Re-emerging Infectious Diseases.

Kyoko Tsukiyama-Kohara present address is Transboundary Animal Diseases Center, Faculty of Agriculture, Kagoshima University, 1-21-24 Korimoto, Kagoshima-city 890-0065, Japan.

*Correspondence to: Kyoko Tsukiyama-Kohara, PhD, Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto City, Kumamoto 860-8556, Japan. E-mail: kkohara@kumamoto-u.ac.jp, kkohara@agri.kagoshima-u.ac.jp

Accepted 16 January 2012

DOI 10.1002/jmv.23250

Published online in Wiley Online Library

(wileyonlinelibrary.com).

A cell line that expresses complete HCV genome (RzM6-LC) was established to investigate the effects of persistent expression of HCV on cell growth [Tsukiyama-Kohara et al., 2004]. A monoclonal antibody (2-152a mAb) against the RzM6-LC cell line was also developed to produce clones that recognize both cell surface and intracellular molecules. As a result, 3β -hydroxysterol Δ 24-reductase (DHCR24) was identified as the target of 2-152a mAb [Nishimura et al., 2009].

DHCR24 is an oxidoreductase with a broad expression pattern and shares homology with a family of flavin-adenine dinucleotide-dependent reductases [Waterham et al., 2001]. In mammals, DHCR24 functions as an enzyme to catalyze the conversion of desmosterol to cholesterol in the post-squalene cholesterol biosynthetic pathway, and it is essential for normal tissue development and maintenance [Waterham et al., 2001; Cramer et al., 2006]. DHCR24 regulates cholesterol synthesis and promotes recruitment of domain components into detergent-resistant membrane fractions [Cramer et al., 2006]. An absence of DHCR24 leads to desmosterolosis—a rare disorder of cholesterol biosynthesis [Waterham et al., 2001]. Expression of DHCR24 is downregulated in areas of the brain affected by Alzheimer's disease [Greeve et al., 2000], suggesting that DHCR24 has alternative functions. Indeed, DHCR24 is also known as seladin-1 (the selective Alzheimer's disease indicator 1), reflecting the association between DHCR24/seladin-1 and the selective vulnerability of the neurons in the affected areas of the brain. High levels of DHCR24/seladin-1 exert protective effects, conferring resistance against oxidative stress and preventing apoptotic cell death [Greeve et al., 2000; Benvenuti et al., 2005; Di Stasi et al., 2005; Luciani et al., 2005; Lu et al., 2008]. Endogenous DHCR24/seladin-1 levels are upregulated in response to acute oxidative stress [Wu et al., 2004; Benvenuti et al., 2006; Kuehnle et al., 2008], whereas the expression declines to low levels upon chronic exposure [Benvenuti et al., 2006; Kuehnle et al., 2008]. Therefore, DHCR24/seladin-1 may be involved in integrating cellular responses to oxidative stress. DHCR24 also functions as a hydrogen peroxide scavenger [Lu et al., 2008]. Based on these findings, DHCR24 may play a crucial role in maintaining cellular physiology by regulating both cholesterol synthesis and cellular defense against oxidative stress.

HCV infection impairs apoptosis induced by oxidative stress and inhibits p53 function via overexpression of DHCR24 [Nishimura et al., 2009]. Augmented expression of DHCR24 also facilitates efficient replication of HCV [Takano et al., 2011b]. Since DHCR24 may play a significant role in viral replication and in the tumorigenicity of the hepatocellular carcinoma related to HCV, the molecular mechanism of overexpression of DHCR24 in response to HCV was examined in the present study.

J. Med. Virol. DOI 10.1002/jmv

MATERIALS AND METHODS

Cell Lines

The HepG2 hepatoblastoma cell line, the HepG2-derived RzM6 cell line, which is capable of conditional control of expression of HCV genome (genotype 1b) based on the *Cre/loxP* system (RzM6-0d, no switching; RzM6-LC, switching of full genome HCV induced by tamoxifen), and HepG2-derived CN5 cell line, in which all HCV proteins were expressed conditionally by cre adenovirus (CN5-Cre) [Tsukiyama-Kohara et al., 2004] were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Using a stable expression system based on lentiviral vectors, HepG2/Lenti cell lines (core, E1, E2, NS2, NS3/4A, NS4B, NS5A, and NS5B) were established [Takano et al., 2011a]. An additional cell line—HepG2-emp—was infected with an empty lentiviral vector. Cells from the human hepatoma HuH-7 cell line were maintained in DMEM supplemented with 10% FBS and 0.4% glucose. The cell lines harboring HCV replicon, namely, R6FLR-N (genotype 1b) and FLR3-1 (genotype 1b), which are derived from HuH-7 [Takano et al., 2011b], were maintained under selective pressure with G418 (500 μ g/ml for R6FLR-N and FLR3-1) in DMEM GlutaMAX (Invitrogen, Carlsbad, CA) containing 10% FBS. Cured/HuH-7 K4 cells—cured of HCV by interferon- α treatment—were maintained in DMEM GlutaMAX containing 10% FBS without G418. The JFH/K4 cell line, which shows persistent infection with the HCV JFH-1 strain, was maintained in DMEM containing 10% FBS. The human fetal hepatic cell line WRL68 was obtained from the American Type Culture Collection and maintained in DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, and 0.1 mM nonessential amino acids. The human hepatoma cell line PLC/PRF/5 was obtained from the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer, Tohoku University, and cultured in Eagle's minimum essential medium supplemented with 10% FBS.

Construction of DHCR24 Promoter Reporter Plasmids

Genomic DNA was extracted from HepG2 cells, and the 5'-flanking sequence of the predicted transcription start site of *DHCR24* (~5 kb) was isolated. The genomic region was inserted upstream of the firefly luciferase gene in pGL3-Basic (Promega, Madison, WI). Deletion constructs of the *DHCR24* promoter region were constructed using restriction enzymes and PCR (sense primer for -4956, 5'-GATCCTCGAGCACTCC-TGCTCACTGAT-3'; sense primer for -2982, 5'-GATCCTCGAGGAGGCTCACATTGTAGAAAG-3'; antisense primer, 5'-GTAGTAGATATCGAAGATAAGC-GAGAGCGG-3') and cloned into pGL3-Basic at the *Xho*I and *Nco*I sites.

Dual Luciferase Reporter Assay

HepG2 cells (1×10^4 cells/well in a 96-well plate) were transfected with each of the 3 *DHCR24* promoter reporter plasmids and their deletion constructs (0.25 μg /well) using cationic lipid (Lipofectamine LTX, Invitrogen). Samples were analyzed with the Dual-Glo Luciferase Assay System (Promega) at 48 h post-transfection, and luminescence was measured using a TriStar LB941 microplate reader (Berthold, Bad Wildbad, Germany). To account for differences in transfection efficiency, the luminescence produced by firefly luciferase (FL) was normalized to that produced by Renilla luciferase (RL), which was expressed by co-transfection with phRL-TK (Promega; 0.025 μg /well).

Electrophoresis Mobility Shift Assay

Nuclear extracts were prepared from 5×10^6 to 1×10^7 cells as described previously [Dignam et al., 1983]. Electrophoresis mobility shift assays (EMSAs) were performed by a nonradioactive method using the DIG Gel Shift Kit (Roche, Indianapolis, IN). Briefly, binding reactions were performed by mixing the following components: 1 μg of poly[d(I-C)], 0.1 μg of poly L-lysine, 40 fmol DIG-labeled double-stranded oligonucleotide probe (HCV response element -167/-140 [28-mer], 5'-CCCCCGCTCGCGCGGCGGCGG-GGAGAA-3'; Sp1 consensus sequence [22-mer], 5'-ATTCGATCGGGGCGGGGCGAGC-3'; MZF1.1-4 consensus sequence [21-mer], 5'-GATCTAAAAGTGGG-GAGAAAA-3'; AP-2 α consensus sequence [26-mer], 5'-GATCGAACTGACCGCCGCGGCCGT-3'), and 10 μg of the nuclear extract in binding buffer (10 mM Tris-HCl, pH 7.5; 50 mM NaCl; 5 mM MgCl₂; 0.5 mM EDTA). Where indicated, reactions were supplemented with unlabeled/competitive oligonucleotide at a 50-fold molar excess concentration before addition of the probe. Mithramycin A (MMA; Sigma, St. Louis, MO), which blocks the binding of Sp1 to target sequences, was added at different final concentrations (2.5, 5, and 10 μM) and incubated at 4°C for 1 h. For supershift assays, 1 μg of monoclonal anti-Myc Tag antibody (Upstate Biotechnology, Lake Placid, NY) was added 30 min prior to addition of the probe. Binding reactions were carried out at 25°C for 30 min and electrophoresed on 6% acrylamide-0.5 \times TBE gels, transferred to positively charged nylon membranes, and detected by a chemiluminescence method (Roche) and a LAS1000 scanner (Fujifilm Co., Tokyo, Japan).

Silencing of Sp1, HCV, and *DHCR24* by siRNA

SP1 Validated Stealth RNAi™ siRNA (VHS40867, Invitrogen) was designed with the BLOCK-iT RNAi designer to target the human Sp1 mRNA sequence. RzM6-0d and RzM6-LC cells (1.5×10^6 cells in a 100-mm dish) were transfected with Sp1 siRNA (final concentration, 30 nM) using Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM (Invitrogen) and incubated for 48 h at 37°C. The siRNAs specific for *DHCR24* and

HCV were designed and utilized as described previously [Nishimura et al., 2009].

Kinase Inhibitors

ATM kinase inhibitor KU55933 (Wako Pure Chemical Industry, Osaka, Japan; final concentration, 10 μM), PI3K inhibitor LY294002 (Cell Signaling Technology, Beverly, MA; 50 μM), and MEK1 inhibitor PD98059 (Cell Signaling Technology; 50 μM) were added to cell cultures, which were incubated for 8 h at 37°C.

Western Blotting

Western blotting was performed as described previously [Tsukiyama-Kohara et al., 2004] with the following primary antibodies: rabbit monoclonal anti-*DHCR24*/Seladin-1 (C59D8; Cell Signaling Technology); rabbit polyclonal anti-Sp1, anti-phospho-Akt (Ser473), and mouse monoclonal anti-phospho-ERK (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); mouse monoclonal anti-HCV core (clone 31-2), E1 (clone 384), E2 (clone 544), NS4A (c14II-2-1), NS5A (32-2), NS5B (14-5), rabbit polyclonal anti-NS2, NS3 (R212), and NS4B (RR10) [Tsukiyama-Kohara et al., 2004]. Phosphorylation of Sp1 was investigated by 5% SDS-PAGE and immunoblotting with a polyclonal antibody against Sp1 phosphorylated at Ser101 (Active Motif, Carlsbad, CA) or Thr453 (Abcam, Cambridge, MA). Detection of γH2AX was performed by 15% SDS-PAGE and immunoblotting with mouse monoclonal anti-phospho-histone H2AX (Ser139) (JBW301; Upstate Biotechnology). Phosphorylated ATM (Ser1981) and ATR (Ser428) were detected by specific antibodies (Cell Signaling Technology). Monoclonal anti-actin (Sigma), anti-histone H1 (Santa Cruz Biotechnology, Inc.), anti-HAUSP (Calbiochem, San Diego, CA), and anti-heat shock protein 90 (Stressgen, Victoria, BC, Canada) primary antibodies were used for normalization of Western blotting. Bound antibody was detected with a horseradish peroxidase-conjugated secondary antibody and visualization using ECL reagents (GE Healthcare, Piscataway, NJ) and an LAS1000 scanner (Fujifilm). Densitometric analysis of protein bands was performed with Image Quant software (Molecular Dynamics, Sunnyvale, CA).

Quantitative PCR and HCV Infection

Total RNA was extracted from cell lines using ISOGEN, and reverse transcription of total RNA (125 ng) was performed with SuperScript III Reverse Transcriptase and Random Primers (Invitrogen). Synthesized cDNA samples were subjected to a TaqMan gene expression assay (Applied Biosystems, Foster City, CA), and the level of expression of *DHCR24* mRNA in each sample was normalized to the level of expression of *GAPDH* mRNA and represented as a ratio of the control (Hep-emp, CN5-Hep, or RzM6-0d). Infection of the human hepatocytes from human liver-*uPA/SCID* chimeric mice with HCV was performed,

and HCV RNA, *DHCR24* mRNA, and 18S rRNA were measured by quantitative PCR (qPCR), as described previously [Takano et al., 2011a].

Statistical Analysis

The Student's *t*-test was used to analyze the statistical significance of the results; *P* values < 0.05 were considered statistically significant.

RESULTS

***DHCR24* Expression Is Upregulated by the Complete HCV Genome But Not by Individual Viral Proteins**

Overexpression of *DHCR24* in human hepatocytes from human liver-uPA/SCID chimeric mice has been

observed after HCV infection (Fig. 1A). The overexpression of *DHCR24* in cells expressing HCV decreased to a similar extent as that observed in control cells following treatment with HCV siRNA (Fig. 1B). Since these findings suggest that overexpression of *DHCR24* is associated with the expression or infection by HCV, the identity of the viral factor involved in the augmentation of expression of *DHCR24* was examined. The level of expression of *DHCR24* mRNA was measured by quantitative RT-PCR (Fig. 1C) in HepG2-derived cell lines that stably express individual HCV proteins (core, E1, E2, NS2, NS3/4A, NS4B, NS5A, or NS5B; Supplementary Fig. 1). The level of expression of *DHCR24* mRNA was slightly higher in the cells expressing NS4B and NS5A than in control cells; however, there was no significant difference in the expression of *DHCR24* mRNA among these cell




Fig. 1. *DHCR24* expression is induced in the presence of the complete HCV genome. A: The amount of HCV RNA in chimeric mice infected with HCV-R6 (genotype 1b) was quantified by qPCR (left panel). The amount of *DHCR24* mRNA was measured, and the ratio to the amount of 18S rRNA was calculated in the tissues (right panel). B: Western blotting of *DHCR24*, HCV core, and actin protein in RzM6-0d and LC cells following treatment with the indicated siRNA. C: Level of *DHCR24* mRNA expression in cell lines with stable expression of individual HCV proteins, the HCV open reading

frame, or the complete HCV genome. Total RNA from HepG2/Lenti cell lines (emp, core, E1, E2, NS2, NS3/4A, NS4B, NS5A, and NS5B), CN5 cell lines (CN5-Hep, CN5-Swa, and CN5-Cre), or RzM6 cell lines (RzM6-0d and RzM6-LC) were prepared, and reverse transcription was performed. Synthesized cDNA was subjected to quantitative PCR. The level of expression of *DHCR24* mRNA for each sample was normalized to that of *GAPDH* mRNA and represented as a ratio of HepG2-emp (**P* < 0.05).

lines. No significant upregulation of *DHCR24* mRNA was observed in the CN5-Cre cell line, which expresses all HCV proteins and is negative for viral replication [Tsukiyama-Kohara et al., 2004]. In contrast, significant upregulation of *DHCR24* was observed in a cell line that expresses the complete HCV genome (RzM6-LC) compared with the expression in HCV-negative control cells (RzM6-0d). Thus, expression of viral proteins alone is insufficient to reproduce the augmentation of expression of *DHCR24* induced by HCV.

DHCR24 Promoter Activity Is Potentiated by the Expression of HCV

The 5'-flanking region contains a number of possible transcriptional regulatory elements, including three candidate-binding motifs for the endoplasmic reticulum

(ER) stress-responsive transcription factor, XBP1. Cellular ER stress is induced in response to the expression of the HCV gene and infection by HCV [Tardif et al., 2005]. Thus, to explore host factors involved in the transcriptional regulation of *DHCR24*, the 5'-flanking genomic region (~5 kb) of *DHCR24* was isolated. Subsequently, *DHCR24* promoter reporter plasmids that contain the 5'-flanking region of *DHCR24* and the firefly luciferase gene were constructed (Fig. 2A). Relevant regions of the promoter were defined by constructing deletion mutants of the 5'-flanking regions, which were analyzed by a dual luciferase reporter assay in the presence or absence of full-length HCV genome expression—resulting from transfection with pCA-Rz [Tsukiyama-Kohara et al., 2004] or the control pCAGGS vector, respectively (Fig. 2B). Progressive shortening of the 5'-flanking regions did not




Fig. 2. *DHCR24* promoter activity is augmented by the expression of HCV. **A**: The 5'-flanking region of *DHCR24* was cloned from HepG2 and inserted upstream of the firefly luciferase gene in pGL3 (-4976/+113). A deletion series of the 5'-flanking regions was also constructed (-2982/+113, -2293/+113, and -515/+113). The black boxes indicate potential binding sites for the ER stress-responsive transcription factor, XBP-1. TSS, transcription start site (+1). **B**: HepG2 cells (1×10^4 cells/well in a 96-well plate) were co-transfected

with each *DHCR24* promoter reporter plasmid (0.25 μ g/well), a Renilla luciferase expression vector (pRL-TK; 0.025 μ g/well), and either an expression vector containing the HCV full-length genome (pCA-Rz; 0.5 μ g/well) or an empty expression vector (pCAGGS). Luciferase activity at 48 h post-transfection is shown as the ratio of firefly luciferase (FL) to Renilla luciferase (RL). Data are shown as the mean \pm SD from 2 representative experiments performed in triplicate (* $P < 0.05$).

result in significant differences in the basal promoter activity (Fig. 2B). The $-515/+113$ construct also produced a significant response in the presence of full-length HCV genome expression.

Additional reporter deletion mutants were constructed to define the region in the *DHCR24* promoter that is responsive to HCV expression. To this aim, potential binding motifs for transcription factors were predicted in the minimized *DHCR24* promoter sequence (nucleotides $-515/+113$; Fig. 3A), and a series of promoter mutants containing sequential 100-bp

deletions was constructed. As shown in Fig. 3A, while the promoter activity of $-515/+113$, $-400/+113$, $-300/+113$, and $-200/+113$ constructs was increased significantly by expression of HCV ($*P < 0.05$), the promoter activity of the $-100/+113$ construct was unchanged. Therefore, an HCV-responsive sequence appears to be located in the upstream region (-200 to -100 bp) from the transcriptional start site of *DHCR24*, which includes sequences with similarity to the consensus-binding motifs for AP-2 α , Sp1, MZF-1, Pax-4, and NF-Y.




Fig. 3. Responsiveness of the *DHCR24* promoter to the expression of HCV. A: A *DHCR24* promoter series with sequential 100-bp deletions was constructed and analyzed as described in the legend to Fig. 2B ($*p < 0.05$). B: An additional deletion series ($-167/+113$, $-144/+113$, and $-120/+113$) was constructed and analyzed as described in (A).

A more detailed deletion series (-167/+113, -144/+113, and -120/+113) was constructed (Fig. 3B) to determine the minimum-binding motif that responds to HCV expression. The responsiveness to the expression of HCV was lost with the removal of the proximal portion (-167 to -145), which includes candidate-binding motifs for AP-2 α , Sp1, and MZF-1. Thus, the identified HCV response element in the *DHCR24* promoter represents the minimum element of DNA sequence required for the promotion of the expression of *DHCR24* induced by HCV.

HCV Expression Augments the Interaction Between the HCV Response Element and the Binding Molecule(s)

Transcription of *DHCR24* is upregulated significantly in RzM6-LC cells that show persistent expression of

HCV [Nishimura et al., 2009]. Therefore, the effect of expression of HCV on the interaction between the HCV response element and its related transcription factor(s) was examined. Nuclear extracts were prepared from RzM6-LC cells, and an electrophoretic mobility shift assay (EMSA) using a DIG-labeled double-stranded oligonucleotide corresponding to the response element (-167/-140, 28 bp; Fig. 4A) was performed. The interaction between the response element and the nuclear factor was increased significantly in nuclear extracts from RzM6-LC cells compared with that in RzM6-0d cells (Fig. 4B). Thus, the binding affinity or quantity of the nuclear factor may be increased by the expression of HCV. The shifted band corresponding to the Sp1 consensus sequence also increased in RzM6-LC cells compared with that in control RzM6-0d cells, whereas no difference was




Fig. 4. The HCV response element mediates the overexpression of *DHCR24* induced by HCV. A: The HCV response element (-167/-140) in the 5'-flanking region of *DHCR24* includes sequences with similarity to the consensus-binding motifs for AP-2 α , Sp1, and MZF-1. B: Nuclear extracts were prepared from RzM6-0d and RzM6-LC cells and subjected to an electrophoresis mobility shift assay (EMSA; 10 μ g/sample) using the DIG-labeled HCV response element (28-bp), Sp1 (22-bp), or MZF-1 (21-bp) probes. Cold probe indicates unlabeled

oligonucleotides. The arrowhead indicates the interaction between the binding factor(s) and each oligonucleotide. C: Cured HuH-7/K4 cells and JFH/K4 cells were co-transfected with each *DHCR24* promoter reporter plasmid (0.5 μ g/well) and phRL-TK (0.05 μ g/well) and analyzed as described in Fig. 2B (**P* < 0.05). (D) Nuclear extracts prepared from cured HuH-7/K4 cells or JFH/K4 cells were subjected to EMSA (25 μ g/sample) using the DIG-labeled HCV response element, Sp1, or MZF-1 probes.

noted in the intensity of the shifted band for the MZF-1 sequence between the RzM6-LC and RzM6-0d cells (Fig. 4B). In contrast to Sp1, the ability of endogenous MZF-1 to bind to its target sequence (affinity and/or amount) in the RzM6-LC cells was approximately equivalent to that observed in the RzM6-0d cells. Thus, MZF-1 is not likely to be involved in the increase, mediated by HCV expression, in the shifted band corresponding to the response element.

HCV Infection Upregulates the Transcriptional Activity of the DHCR24 Promoter Through HCV Response Element

An *in vitro* model of HCV infection that replicates the entire HCV life cycle [Wakita et al., 2005] was used to confirm that transcription of *DHCR24* was mediated through the HCV response element. JFH/K4 cells, which show persistent infection with the HCV JFH-1 strain [Wakita et al., 2005], and control cells (cured HuH-7/K4) were transfected with the *DHCR24* promoter reporter plasmids, and promoter activity was measured. While *DHCR24* promoter reporters that included the HCV response element (−515/+113, −200/+113, and −167/+113) displayed significantly higher activity in JFH/K4 cells than in control cells, no difference was seen between the JFH/K4 cells and control cells transfected with the reporter lacking the HCV response element (−144/+113; Fig. 4C). These results suggest that the transcriptional activity of the *DHCR24* promoter was upregulated by HCV infection in a manner dependent on the response elements. Furthermore, augmentation of complex formation with the response element and the Sp1 probe was confirmed by EMSA using nuclear extracts from JFH/K4 and cured HuH-7/K4 cells (Fig. 4D).

Sp1 Binds to the HCV Response Element

The HCV response element (−167/−140) includes candidate-binding motifs for Sp1, MZF-1, and AP-2 α (Fig. 4A). However, expression of AP-2 is repressed in the HepG2 cell line from which RzM6-LC cells are derived [Williams et al., 1988]. Thus, binding of AP-2 α to the response element was investigated by a supershift assay using anti-Myc and nuclear extract from HepG2 cells transfected with a Myc-tagged AP-2 α expression vector (Fig. 5A). The mobility of the DNA-AP-2 α complex was supershifted by the addition of anti-Myc (lane 6) but not control IgG (lane 5), whereas an additional shifted band corresponding to the response element was not observed after addition of anti-Myc (lane 3). Therefore, although exogenous AP-2 α protein expressed in HepG2 cells binds to the AP-2 α consensus sequence, it does not bind to the HCV response element.

The ability of Sp1 to form a DNA-protein complex with the HCV response element was investigated by performing EMSAs in the presence of mithramycin A (MMA)—a GC-specific DNA-binding antibiotic that binds to the GC-box in the promoter to block binding

of Sp1 or other Sp family proteins [Blume et al., 1991]. As shown in Fig. 5B, MMA (2.5, 5.0, and 10 μ M) inhibited complex formation in a dose-dependent manner. In contrast, the formation of DNA-protein complexes with the MZF-1 probe was not affected by the addition of MMA, suggesting that the inhibition mediated by MMA was specific for the GC box-Sp1, and that complex formation with the response element requires the Sp1 binding site. A supershift assay using nuclear extract from HepG2 cells transfected with a Myc-tagged Sp1 expression vector and anti-Myc was also performed (Supplementary Fig. 2). The mobility of the HCV response element and the Sp1 consensus sequence was supershifted partially by addition of anti-Myc (lanes 3 and 6). The effect of silencing the expression of Sp1 with small interfering RNA (siRNA) was analyzed by EMSA using nuclear extracts from Sp1-knockdown RzM6-0d and RzM6-LC cells (Fig. 5C). DNA-protein complexes with the response element or the Sp1 probe were not observed (lanes 2, 4, 6, and 8); however, formation of DNA-MZF-1 complexes was not influenced by siRNA treatment (lanes 9–12). Immunoblotting was used to confirm efficient silencing of the Sp1 protein in cells used to generate the nuclear extracts (Fig. 5D). A significant decrease in the expression of *DHCR24* was observed in the cytosolic fraction from RzM6 cells transfected with siRNA specific for Sp1 (Fig. 5D). Thus, these results indicate that Sp1, but neither AP-2 α nor MZF-1, bound to the HCV response element, and that Sp1 may play an important role in the transcriptional regulation of *DHCR24*.

Transcriptional Regulation of DHCR24 Through the HCV Response Element Is Mediated by Oxidative Stress

DHCR24 functions as a mediator of the cellular response to oxidative stress [Greeve et al., 2000; Benvenuti et al., 2005; Di Stasi et al., 2005; Luciani et al., 2005; Lu et al., 2008] and is a hydrogen peroxide scavenger [Lu et al., 2008]. Expression of the *DHCR24* gene is also induced in response to oxidative stress [Wu et al., 2004; Benvenuti et al., 2006; Kuehnle et al., 2008]. Expression of the HCV gene elevates the level of reactive oxygen species (ROS) via dysregulation of ER-mediated calcium homeostasis, which results in oxidative stress [Tardif et al., 2005]. Therefore, the role of oxidative stress induced by HCV in the regulatory mechanism of the expression of *DHCR24* was examined. HepG2 cells were treated with hydrogen peroxide (H₂O₂) and transfected with reporter plasmids containing the *DHCR24* promoter deletion mutants. Measurement of promoter activity revealed a significant increase in transcription in response to oxidative stress (H₂O₂) for *DHCR24* promoters containing the HCV response element (−4976/+113, −2982/+113, −515/+113, and −167/+113) but not for the promoter lacking the response element (−144/+113; Fig. 6A). Therefore, enhanced transcription in response to oxidative stress by reporter constructs




Fig. 5. Sp1 binds to the HCV response element. A: Nuclear extract was prepared from HepG2 cells transfected with pcDNA6-AP-2α-myc and subjected to EMSA (10 μg/sample) using DIG-labeled HCV response element or AP-2α probes (26-bp). For a supershift analysis of myc-tagged AP-2α, anti-Myc, or control IgG was added to the binding reaction. The closed arrowhead indicates the interaction between the binding factor(s) and each oligonucleotide, and an additional interaction with antibody is indicated by an open arrowhead. B: Nuclear extract from HepG2 cells was pre-incubated at 4°C for 1 h

with different concentrations (2.5, 5, and 10 μM) of mithramycin A (MMA) and subjected to EMSA (10 μg/sample) using the DIG-labeled HCV response element, Sp1, or MZF-1 probes. C: Nuclear extracts were prepared from RzM6 cells transfected with Sp1 siRNA or control siRNA and subjected to EMSA (10 μg/sample) using the DIG-labeled HCV response element, Sp1, or MZF-1 probes. D: Expression of Sp1, DHCR24, and other proteins was detected in both the nuclear fraction (N), used for the EMSA shown in Fig. 4C, and in the cytosolic-membrane fraction (C).

containing the *DHCR24* promoter may be mediated through the HCV response element. The formation of complexes containing the response element or Sp1 probe was increased markedly in the nuclear extracts from the H₂O₂-treated HepG2 cells (Fig. 6B) or other hepatic cell lines (Supplementary Fig. 3), suggesting that oxidative stress enhances the binding affinity of Sp1 to the HCV response element.

Overexpression of *DHCR24* in M6-LC Cells Is Blocked by an ROS Scavenger

The increase in the expression of *DHCR24* induced by oxidative stress can be blocked by treatment with an ROS scavenger, *N*-acetylcysteine (NAC) [Wu et al., 2004], which is a precursor of the potent biological antioxidant glutathione. The H₂O₂-induced overexpression




Fig. 6. Oxidative stress increases the transcription of *DHCR24* through the HCV response element and Sp1. A: HepG2 cells (1×10^4 cells/well in a 96-well plate) were co-transfected with individual *DHCR24* promoter reporter plasmids (0.5 μ g/well) and pRL-TK (0.05 μ g/well). Forty-four hours post-transfection, cells were treated with or without 1 mM H₂O₂ for 4 h and analyzed as described in Fig. 2B (* $P < 0.05$). B: Nuclear extracts prepared from H₂O₂-treated (1 mM, 4 h) or untreated HepG2 cells were subjected to EMSA (10 μ g/sample) using the DIG-labeled HCV response element, Sp1, or MZF-1 probes. Densitometric analysis of shifted bands was performed using the Image Quant software. Data are shown as the mean \pm SD from triplicate quantifications of two representative experiments (* $P < 0.05$).

of *DHCR24* was inhibited by pre-treatment with NAC and blocked partially by NAC treatment after the induction of oxidative stress (~50% suppression; Fig. 7A). The enhanced expression of *DHCR24* in RzM6-LC cells decreased after 12 or 24 h of treatment with NAC without influencing the level of expression of HCV, suggesting that overexpression of *DHCR24* in cells expressing HCV is mediated through oxidative stress.

Overexpression and Enhanced Phosphorylation of Sp1 in the Cells Expressing HCV

Sp1 is a transcription factor that is activated in response to a variety of cellular stressors, including oxidative stress [Schafer et al., 2003; Chu and Ferro, 2006; Dasari et al., 2006; Qin et al., 2009; Lin et al., 2011]. Thus, Sp1 may play an important role in linking oxidative stress and augmentation of *DHCR24* transcription in cells expressing HCV. Sp1 was overexpressed significantly in RzM6-LC cells treated with H₂O₂ compared with the control cells (Fig. 8A). Phosphorylation of Sp1 at Ser101 was also elevated

under oxidative stress. Both the basal level and phosphorylation status of nuclear Sp1 were higher in the presence of HCV (RzM6-LC cells) than in the absence of HCV (RzM6-0d cells; Fig. 8B).

Phosphorylation of Sp1 at Ser101 is a target of the DNA damage signaling pathway mediated by ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related) kinases [Olofsson et al., 2007; Iwahori et al., 2008]. As shown in Fig. 8C, phosphorylation of Sp1 at Ser101 was no longer detectable following pre-treatment with an ATM kinase inhibitor (KU55933) before exposure to H₂O₂. In contrast, phosphorylation was not affected by other kinase inhibitors (phosphatidylinositol-3 kinase inhibitor, LY294002 or MEK1 inhibitor, PD98059). Similarly, phosphorylation of Sp1 at Thr453, which is important for transcriptional activation of Sp1 [Milanini-Mongiat et al., 2002; D'Addario et al., 2006; Hsu et al., 2006; Lin et al., 2011], was not seen in response to oxidative stress following treatment with KU55933 (Fig. 8C). The induction of expression of *DHCR24* after H₂O₂ exposure was suppressed significantly by treatment with KU55933 or NAC, which corresponds with inhibition of Sp1 phosphorylation. In the presence of MMA, the phosphorylation of Sp1 was not inhibited. However, since MMA blocks the binding of Sp1 [Blume et al., 1991], the induction of expression of *DHCR24* by H₂O₂ was inhibited. Impairment of *DHCR24* induction by H₂O₂ was also observed after treatment with siRNAs targeting ATM (Supplementary Fig. 4).

Studies on the relationship between HCV and ATM have reported that the interaction of NS3/4A with ATM results in delayed de-phosphorylation of both phosphorylated ATM and phosphorylated histone H2AX at Ser139 (γ H2AX), which acts as a substrate for ATM in response to DNA damage [Lai et al., 2008]. In the present study, delayed de-phosphorylation of γ H2AX was also observed in HCV replicon cells (Supplementary Fig. 5), which corresponded with increased phosphorylation of the H2AX Ser139 residue in cells expressing HCV (Fig. 8). Similarly, phosphorylation of ATM was sustained in HCV replicon cells (Supplementary Fig. 6). Therefore, DNA repair may be impaired in cells expressing or replicating HCV, resulting in sustained DNA damage. As a result, downstream substrates such as Sp1 Ser101 and Thr453 residues or the H2AX Ser139 residue may be phosphorylated to a greater extent in cells expressing HCV compared with control cells in the basal state or cells under oxidative stress (Fig. 8A and B).

Taken together, these results indicate that the oxidative stress induced by HCV may produce quantitative as well as qualitative activation of Sp1, thereby resulting in augmentation of *DHCR24* transcription.

DISCUSSION

HCV establishes chronic infection and induces persistent overexpression of *DHCR24* in human hepatocytes [Nishimura et al., 2009]. HCV also confers




Fig. 7. Overexpression of *DHCR24* in the cells expressing HCV is blocked by treatment with an oxidative stress scavenger. **A:** HepG2 cells were treated without (lanes 1, 4, and 6) or with (lanes 2 and 5) NAC (10 mM, 8 h). Cells treated with H₂O₂ (1 mM, 4 h) were also treated with 10 mM NAC for 8 h either before (pre; lanes 3 and 4) or after (post; lanes 5 and 6) H₂O₂ exposure. Whole-cell lysates (40 µg/lane) were analyzed by 10% SDS-PAGE and immunoblotting using a *DHCR24*/Seladin-1 mAb. Immunoblotting with an actin mAb served as the internal loading control. The ratio of *DHCR24*/actin was normalized to that of untreated cells (lane 1). **B:** RzM6-LC cells were treated with NAC (10 mM) for 12 h (lane 2) or 24 h (lane 4). Whole-cell lysates were analyzed as described in (A). The ratio of HCV core to actin protein was also calculated. Experiments were performed three times, and representative results are shown.

resistance to the apoptosis induced by oxidative stress and suppresses p53 activity by blocking nuclear p53 acetylation and increasing the interaction between p53 and HDM2 (p53-specific E3 ligase) in the cytoplasm, which may be mediated by inhibition of p53 degradation. Thus, the augmentation of *DHCR24* by HCV reflects the tumorigenicity of hepatocytes. The present study identified the genomic region of *DHCR24* that is responsive to HCV, and showed that this response is mediated through the activation of Sp1 induced by oxidative stress. In general, expression of the HCV gene elevates the levels of ROS through dysregulation of ER-mediated calcium homeostasis [Tardif et al., 2005]. In healthy cells, ROS usually exist in equilibrium with antioxidants that scavenge ROS and prevent cellular injury. However, this critical balance may be disrupted in the cells infected with HCV, resulting in the accumulation of

ROS and the development of constitutive oxidative stress.

Sp1 is a member of the Sp/KLF family of transcription factors that bind to GC elements of promoters [Black et al., 2001; Kaczynski et al., 2003; Chu and Ferro, 2005; Li and Davie, 2010]. Under a variety of endogenous and exogenous stimuli—including oxidative stress and DNA damage—activation of Sp1 may be mediated via induction of expression of Sp1 and post-translational modifications such as acetylation, sumoylation, O-linked glycosylation, and phosphorylation. Sp1 is phosphorylated by several kinases, including DNA-dependent protein kinase, casein kinase II, and cyclin A/cdk2, which exert both positive and negative effects on transcription [Jackson et al., 1990; Armstrong et al., 1997; Fojas de Borja et al., 2001; Ryu et al., 2003]. Sp1 is the only Sp/KLF family member to contain putative consensus SQ/TQ cluster domains within the transactivation domains, which suggests that Sp1 is a substrate of the PI3K-related kinases, for example, ATM, DNA-dependent protein kinase, and ATR. Indeed, Sp1 is a target of the ATM-dependent DNA damage response pathway [Iwahori et al., 2007, 2008; Olofsson et al., 2007]. ATM plays a central role in orchestrating molecular events involved in double-strand break signaling, which is mediated via the phosphorylation of a variety of substrate proteins—including p53 and BRCA1 transcription factors—involved in the DNA damage response. As a result, these phosphorylation events lead to cell cycle checkpoint activation, DNA repair, altered gene expression patterns, and/or apoptosis [Shiloh, 2006].

Given the role of Sp1 in oxidative stress [Schafer et al., 2003; Chu and Ferro, 2006; Dasari et al., 2006; Rojo et al., 2006; Qin et al., 2009; Lin et al., 2010], Sp1 may be regulated by the oxidative stress induced by HCV and the subsequent phosphorylation, which depends on ATM. However, little is known regarding the regulation of Sp1 in response to DNA damage. Although the precise role of phosphorylation of Sp1 at Ser101 in the DNA damage response is unclear, the similar kinetics of Sp1 and γ H2AX phosphorylation [Olofsson et al., 2007] suggest that Sp1 is an early target of the DNA damage response pathway. Thus, Sp1 may be involved in modulating the cellular response to DNA damage to prevent cell death [Ryu et al., 2003]. Phosphorylation of Sp1 at Ser101 and histone H2AX, which occurs in parallel in response to oxidative stress, was enhanced in cells expressing HCV compared with that observed in control cells (Fig. 8A). Interestingly, augmentation of Sp1 phosphorylation in parallel with histone H2AX phosphorylation was also detected for cells expressing HCV in the basal state (Fig. 8A and B), which may be primarily due to the increase in endogenous Sp1 protein (Fig. 8A and B). In support of these results, enhanced phosphorylation of Ser101 on Sp1 occurs upon HSV-1 infection, and is mediated by ATM [Iwahori et al., 2007]. Thus, increased phosphorylation of Sp1 and γ H2AX in cells expressing HCV is likely to reflect the higher activity




Fig. 8. Overexpression and elevated phosphorylation of Sp1 in the cells expressing HCV. **A:** RzM6-0d and RzM6-LC cells were treated with or without H_2O_2 (1 mM, 4 h). Whole-cell lysates (15 μ g/lane) were analyzed by 15% SDS-PAGE and immunoblotting using phospho-H2AX (Ser139) (γ H2AX) and HCV core mAbs. An actin mAb served as an internal loading control. Whole-cell lysates (25 μ g/lane) were analyzed by 5% SDS-PAGE and immunoblotting using anti-Sp1 (phosphorylated Sp1 and native Sp1, as indicated) and anti-phospho-Sp1 (Ser101) was performed. **B:** RzM6-0d and RzM6-LC cells were fractionated to produce nuclear (N) and cytosolic-membrane fractions (C). Fractionated samples (15 μ g/lane) were analyzed as described in (A). The ratio of phosphorylated Sp1 to Sp1 protein is indicated. Immunoblotting using anti-HAUSP served as a

high-molecular-weight loading control. **C:** RzM6-0d cells were pre-treated for 8 h with NAC (10 mM), MMA (10 μ M), KU55933 (KU; 10 μ M), LY294002 (LY; 50 μ M), or PD98059 (PD; 50 μ M) and incubated for 4 h in the absence or presence of H_2O_2 (1 mM). Whole-cell lysates (40 μ g/lane) were analyzed by 5% SDS-PAGE and immunoblotting using anti-phospho-Sp1 (Ser101), (Thr453), and polyclonal anti-Sp1 (white arrowhead, phosphorylated Sp1; black arrowhead, native Sp1). Detection of HAUSP was performed to confirm the quantity of loaded protein in each lane. Whole-cell lysates (25 μ g/lane) were analyzed simultaneously by 10% SDS-PAGE and immunoblotting using anti-DHCR24/seladin-1 mAb, anti-phospho-Akt (Ser473), and anti-phospho-ERK antibodies.

of ATM, which may result from the accumulation and frequency of DNA damage caused by increased generation of endogenous ROS.

Oxidative stress is a common mechanism of liver injury [Loguercio and Federico, 2003] and is mediated by the direct effects of ROS on signal transduction pathways, including extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinases (MAPKs), which act as downstream kinases in the MAPK cascade to phosphorylate Sp1 Thr453/739 residues [Milanini-Mongiat et al., 2002; D'Addario et al., 2006; Hsu et al., 2006; Chuang et al., 2008; Lin et al., 2011]. These signal transduction pathways are also stimulated by oxidative stress in the hepatic cells expressing or

replicating HCV, [Qadri et al., 2004; Burdette et al., 2010; Lin et al., 2010]. Therefore, oxidative stress in response to HCV may induce downstream signaling pathways, such as ERK1/2, JNK, and p38 MAPK as well as ATM/ATR, to activate Sp1 via post-translational modifications.

Sp1 is a host factor activated by several viral proteins, including HIV-1 Vpr, and HTLV-1 Tax [Peng et al., 2003; Amini et al., 2004; Chang et al., 2005; Zhang et al., 2009]. The HCV core and NS5A proteins also activate Sp1 [Lee et al., 2001; Xiang et al., 2010]. The HCV core upregulates the DNA-binding activity and phosphorylation of Sp1 [Lee et al., 2001], and NS5A may also exert a similar effect on Sp1 activity. However, a physical interaction between these